secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001193125-25-023130
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics pauses BEACON-IPF Phase 2b trial of bexotegrast after DSMB review
--------------------------------------------------------------------------------

- Voluntarily paused enrollment and dosing in BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis (IPF).
- Pause follows prespecified data review and recommendations by independent Data Safety Monitoring Board (DSMB).
- Patients currently enrolled in the trial will remain and be monitored while data is reviewed; blinding maintained.
- Company has informed trial investigators and is in process of informing global regulatory authorities.
- No details provided on DSMB rationale; lead asset trial halt likely materially negative for PLRX stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312525023130/0001193125-25-023130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312525023130/d931376d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-023130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer